All In Biotech

Drug Trial Radar · NCT07420283

A Study of Brenipatide in Participants With Opioid Use Disorder

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

465

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.

Conditions

  • Opioid Use Disorder

Interventions

  • BrenipatideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

  • BuprenorphineDrug

    Administered sublingual or buccal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Weeks of Abstinence from Opioid Use Defined by Both Negative Urine Drug Screen (UDS) and no Self-Report of Opioid use Based on Timeline Followback (TLFB)Time frame: Week 13 up to Week 24
  2. Achievement of ≥80% Weeks of Abstinence from Opioid Use Defined by Both Negative UDS and no Self-Report of Opioid Use Based on TLFBTime frame: Week 13 up to Week 24

Locations

68 sites in 4 countries. Site status is shown where the registry gives one.

  • NoesisPharma - Phoenix - East Shea Boulevard

    Phoenix, Arizona · Recruiting

  • Pillar Clinical Research- Little Rock

    Little Rock, Arkansas · Recruiting

  • Woodland International Research Group

    Little Rock, Arkansas · Recruiting

  • Ark Clinical Research - Fountain Valley

    Fountain Valley, California · Recruiting

  • Center on Substance Use and Health (CSUH)

    San Francisco, California · Recruiting

  • UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay

    San Francisco, California · Recruiting

  • Bradenton Research Center, Inc.

    Bradenton, Florida · Recruiting

  • K2 Medical Research - Daytona Beach

    Daytona Beach, Florida · Recruiting

  • NextPhase Research Florida - Hollywood

    Hollywood, Florida · Recruiting

  • Accel Research Sites - Lakeland Clinical Research Unit

    Lakeland, Florida · Recruiting

  • Life Arc Research Centers - Miami

    Miami, Florida · Recruiting

  • Wellness Research Center

    Miami, Florida · Not yet recruiting

  • Advanced Research for Health Improvement, LLC

    Naples, Florida · Recruiting

  • Innovative Research Institute - Port Charlotte

    Port Charlotte, Florida · Recruiting

  • Better Years Ahead Medical Center

    Tampa, Florida · Recruiting

  • Health Synergy Clinical Research

    West Palm Beach, Florida · Not yet recruiting

  • Neuroscience Research Institute - West Palm Beach

    West Palm Beach, Florida · Recruiting

  • Accelerated Clinical Trials

    Snellville, Georgia · Not yet recruiting

  • Re:Cognition Health - Chicago

    Chicago, Illinois · Recruiting

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana · Recruiting

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Recruiting

  • Maryland Treatment Centers - Mountain Manor Treatment Center

    Baltimore, Maryland · Recruiting

  • Maryland Treatment Centers - Avery Road Treatment Center

    Rockville, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Voltaire Springfield

    Springfield, Massachusetts · Not yet recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • SKY Integrative Medical Center/SKYCRNG

    Ridgeland, Mississippi · Recruiting

  • CNS Veritas

    New York, New York · Not yet recruiting

  • Adams Clinical Harlem

    New York, New York · Recruiting

  • Adams Clinical Bronx

    The Bronx, New York · Recruiting

  • Monroe Biomedical Research

    Monroe, North Carolina · Not yet recruiting

  • New Dimension Group

    Rose Hill, North Carolina · Not yet recruiting

  • Ohio Clinical Trials

    Columbus, Ohio · Recruiting

  • Rivus Wellness and Research Institute

    Oklahoma City, Oklahoma · Not yet recruiting

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Penn Medicine: University of Pennsylvania Health System

    Philadelphia, Pennsylvania · Recruiting

  • Brown University School of Public Health

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Not yet recruiting

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.